A six-month head-to-head superiority clinical study of SEL-212 compared to Krystexxa
Phase of Trial: Phase II
Latest Information Update: 03 Jan 2019
At a glance
- Drugs SEL 212 (Primary) ; Pegloticase
- Indications Gout
- Focus Therapeutic Use
- Sponsors Selecta Biosciences
- 03 Jan 2019 According to a Selecta Biosciences media release, of an interim six-month data readout is projected for the fourth quarter 2019 with a full statistical superiority data analysis expected in the first quarter of 2020.
- 08 Nov 2018 According to a Selecta Biosciences media release, the company expects to start this study in the first quarter of 2019, with interim data readouts expected in 2019 and full data presentation anticipated in first quarter of 2020.
- 27 Aug 2018 New trial record